![Apixaban (Eliquis®) – Drug-Drug-Interaction Considerations in COVID-19 Patients with Coagulation Abnormalities - Anesthesia Patient Safety Foundation Apixaban (Eliquis®) – Drug-Drug-Interaction Considerations in COVID-19 Patients with Coagulation Abnormalities - Anesthesia Patient Safety Foundation](https://www.apsf.org/wp-content/uploads/ddi/2020/apixaban-direct-factor-xa-inhibitor-1024x576.jpg)
Apixaban (Eliquis®) – Drug-Drug-Interaction Considerations in COVID-19 Patients with Coagulation Abnormalities - Anesthesia Patient Safety Foundation
![Targeted inhibitors of P-glycoprotein increase chemotherapeutic-induced mortality of multidrug resistant tumor cells | Scientific Reports Targeted inhibitors of P-glycoprotein increase chemotherapeutic-induced mortality of multidrug resistant tumor cells | Scientific Reports](https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41598-018-19325-x/MediaObjects/41598_2018_19325_Fig1_HTML.jpg)
Targeted inhibitors of P-glycoprotein increase chemotherapeutic-induced mortality of multidrug resistant tumor cells | Scientific Reports
![ASCP10-Don't use strong CYP3A4 and P-glycoprotein inhibitors or inducers with Direct Oral Anticoagulants (DOACs) and periodically assess the medication regimen for such drug-drug interactions. | Choosing Wisely ASCP10-Don't use strong CYP3A4 and P-glycoprotein inhibitors or inducers with Direct Oral Anticoagulants (DOACs) and periodically assess the medication regimen for such drug-drug interactions. | Choosing Wisely](https://www.choosingwisely.org/wp-content/uploads/2021/05/ASCP-CLR-logo-NoTag-RGB-01smaller.png)
ASCP10-Don't use strong CYP3A4 and P-glycoprotein inhibitors or inducers with Direct Oral Anticoagulants (DOACs) and periodically assess the medication regimen for such drug-drug interactions. | Choosing Wisely
![Table 1.4 from P-glycoprotein inhibition as a strategy to increase drug delivery across the blood-brain barrier: focus on antidepressants | Semantic Scholar Table 1.4 from P-glycoprotein inhibition as a strategy to increase drug delivery across the blood-brain barrier: focus on antidepressants | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/cb07bdccd7c7e764d8e619d6a15ecce23b7d8307/49-Table1.4-1.png)
Table 1.4 from P-glycoprotein inhibition as a strategy to increase drug delivery across the blood-brain barrier: focus on antidepressants | Semantic Scholar
![Pharmaceutics | Free Full-Text | Pharmaceutical Formulations with P- Glycoprotein Inhibitory Effect as Promising Approaches for Enhancing Oral Drug Absorption and Bioavailability Pharmaceutics | Free Full-Text | Pharmaceutical Formulations with P- Glycoprotein Inhibitory Effect as Promising Approaches for Enhancing Oral Drug Absorption and Bioavailability](https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-13-01103/article_deploy/html/images/pharmaceutics-13-01103-g002.png?1627018720)
Pharmaceutics | Free Full-Text | Pharmaceutical Formulations with P- Glycoprotein Inhibitory Effect as Promising Approaches for Enhancing Oral Drug Absorption and Bioavailability
![SciELO - Brasil - Overview of P-glycoprotein inhibitors: a rational outlook Overview of P-glycoprotein inhibitors: a rational outlook SciELO - Brasil - Overview of P-glycoprotein inhibitors: a rational outlook Overview of P-glycoprotein inhibitors: a rational outlook](https://minio.scielo.br/documentstore/2175-9790/TjKWXnrBxMvtPZWgNMDFxMM/05530cfb309b03172203d0f52ba052ed9fd5e2e9.jpg)
SciELO - Brasil - Overview of P-glycoprotein inhibitors: a rational outlook Overview of P-glycoprotein inhibitors: a rational outlook
![SciELO - Brasil - Overview of P-glycoprotein inhibitors: a rational outlook Overview of P-glycoprotein inhibitors: a rational outlook SciELO - Brasil - Overview of P-glycoprotein inhibitors: a rational outlook Overview of P-glycoprotein inhibitors: a rational outlook](https://minio.scielo.br/documentstore/2175-9790/TjKWXnrBxMvtPZWgNMDFxMM/b6b81950a2e296abac549644d5c6848b44165ac2.jpg)